# US 2004/0018562 A1 · Receptor detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018562 A1
- Document ID: US20040018562A1
- Status: Published application
- Kind: A1
- Application number: 10/448,609
- Filed: 2003-05-29
- Published: 2004-01-29
- Earliest claimed: 2002-05-29
- Inventors: Riaz Rouhani; Tabassum Naqvi; Rajendra Singh
- Web page: https://patentgrep.com/patent/US20040018562A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- C12Q 1/34: involving hydrolase
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Improved results are obtained using in an enzyme fragment complementation assay, as an enzyme donor a fragment of β-galactosidase of from 36 to 50 amino acids joined to a ligand capable of binding to a receptor other than an immunoglobulin or fragment thereof. Conveniently, for enzyme assays, enzyme binding site inhibitors are conjugated to the enzyme donor, whereby binding of the enzyme to the binding site inhibitor results in a reduction in the turnover rate of β-galactosidase in the presence of EA and a substrate capable of producing a detectable signal. Analogously, ligands for membrane receptors may be conjugated to the ED for measurement of membrane receptors.

## Claims

### Claim 1

In a method for performing a determination of a binding event of a protein receptor with a ligand, wherein said protein receptor is other than an antibody or polyvalent fragment thereof, enzyme donor fragment of β-galactosidase is used as the label for complexation with enzyme acceptor fragment, the improvement which comprises:
employing as the enzyme donor a β-galactosidase fragment of from 36 to 50 amino acids.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said enzyme donor fragment comprises from 1-2 cysteines proximal to the termini.

### Claim 3 (depends on 1)

A method according to claim 1, wherein said protein receptor is an enzyme.

### Claim 4 (depends on 1)

A method according to claim 1, wherein said protein receptor is a membrane receptor.

### Claim 5 (depends on 1)

A method according to claim 1, wherein said protein receptor is a component of an intact cell.

### Claim 6 (depends on 1)

A method according to claim 1, wherein said protein receptor is present in an assay medium.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said ED is of from 36 to 45 amino acids and comprises from 1-2 cysteines proximal to the termini.

### Claim 8

A method for detecting the active site of an enzyme, said method comprising:
combining in an assay medium a complex formed from a sample suspected of comprising said enzyme and an ED conjugate of ED of from 36 to 50 amino acids bonded to an enzyme binding site inhibitor having a binding constant of at least about 10−8 M, with EA and a β-galactosidase substrate producing a detectable product; and
detecting the resulting signal as indicative of the presence of said enzyme.

### Claim 9 (depends on 7)

A method according to claim 7, wherein said complex is formed by mixing said sample with said ED conjugate and incubating for at least 15 min.

### Claim 10 (depends on 7)

A method according to claim 7, wherein said ED is of from 36 to 45 amino acids and comprises frmom 1-2 cysteines proximal to the termini.

### Claim 11 (depends on 7)

A method according to claim 7, wherein said signal is light emission.

### Claim 12 (depends on 7)

A method according to claim 7, wherein said enzyme is PKC-α and said binding site inhibitor is staurosporine.

### Claim 13

A complex of a receptor and a conjugate of a ligand binding said receptor bonded to an ED of from 36 to 50 amino acids.

### Claim 14 (depends on 12)

A complex according to claim 12, wherein said ligand is bound at both the N- and C-termini of said ED.

### Claim 15 (depends on 12)

A complex according to claim 12, wherein said ED is of from 36 to 45 amino acids.

### Claim 16 (depends on 12)

A complex according to claim 12, wherein said receptor is an enzyme.

### Claim 17 (depends on 12)

A complex according to claim 12, wherein said receptor is a membrane receptor.

### Claim 18 (depends on 12)

A complex according to claim 12, wherein said ligand is a cyclic organic molecule of from 125 to 1000 Dal.

### Claim 19 (depends on 18)

A complex according to claim 18, wherein said ligand is a steroid.

### Claim 20 (depends on 18)

A complex according to claim 18, wherein said ligand is a nucleotide.

### Claim 21 (depends on 1)

A kit comprising an enzyme donor a β-galactosidase fragment of from 36 to 50 amino acids conjugated to a receptor ligand, a source of a β-galactosidase enzyme acceptor, optionally a β-galactosidase substrate, and instructions for performing the method according to claim 1.

### Claim 22 (depends on 21)

A kit according to claim 21, wherein said instructions are in electronic format.
